Decoding Sjogren’s Disease: A Clinical Deep Dive – Season 2

Health Monitor Network
  • 0.0 (0)
  • Science

Building on an award-winning first season, Decoding Sjogren’s Disease: Season 2 answers the tough question: What happens after diagnosis? Phenotyping, biomarker surveillance, biologic candidacy, treatment timing — most clinicians are still making decisions with scores that were never built to guide treatment. Over five new episodes, the world’s leading Sjogren’s experts offer a masterclass on the mechanistic drivers, tracking tools, and precision medicine strategies defining the next era of Sjogren’s therapy. The standard of care for this disease is about to meaningfully shift. Is your practice keeping up? This content is intended for medical professionals only.

Episodes

  1. 3d ago

    Mechanistic Drivers of Sjogren’s

    Sjogren's has long been reduced to its most visible symptoms, but the biology tells a more complex story. In this episode, Dr. Nancy Carteron walks through the immune mechanisms driving Sjogren's from the inside out, including the interplay between Type I interferon signaling and B-cell hyperactivity, how germinal center structures in the salivary glands fuel ongoing autoimmunity, and why BAFF dysregulation may be a critical and underappreciated therapeutic target. Nancy also addresses the systemic reach of the disease into the lungs, nervous system, and beyond, and explains why a handful of routine lab values can help clinicians connect the dots earlier. About Dr. Nancy Carteron Dr. Carteron is a Professor at the University of California, Berkeley, and the immediate past chair of the Medical and Scientific Advisory group of the Sjogren’s Foundation. She currently sees patients at the Interdisciplinary Sjogren’s Clinic at UC Berkeley. She is a nationally recognized leader in clinical innovation and research for Sjogren’s disease. In this episode, we explore: (00:00) Connecting routine lab values to systemic Sjögren's disease (02:00) Why Sjögren's is no longer understood as a glandular condition (02:34) B-cell hyperactivity and where drug targets are strongest (03:29) Type I interferon as a loop, not a linear trigger (05:04) Germinal centers: drivers of autoimmunity or markers of established disease (06:54) BAFF dysregulation and why blocking it improves clinical outcomes (08:23) Tolerance checkpoint failures and what cancer immunotherapy is teaching us (10:11) Lung involvement and lymphocyte infiltration beyond the salivary glands (11:22) Ro52 and Ro60 as distinct antibodies with distinct phenotypic implications (12:44) Neurologic manifestations including ganglionopathy and what clinicians miss (14:22) If you take one thing from this episode... Learn more about your ad choices. Visit podcastchoices.com/adchoices

    Mechanistic Drivers of Sjogren’s
  • 1 Episode

About

Building on an award-winning first season, Decoding Sjogren’s Disease: Season 2 answers the tough question: What happens after diagnosis? Phenotyping, biomarker surveillance, biologic candidacy, treatment timing — most clinicians are still making decisions with scores that were never built to guide treatment. Over five new episodes, the world’s leading Sjogren’s experts offer a masterclass on the mechanistic drivers, tracking tools, and precision medicine strategies defining the next era of Sjogren’s therapy. The standard of care for this disease is about to meaningfully shift. Is your practice keeping up? This content is intended for medical professionals only.

Information